Home / Stock ratings / GHRS
Stock rating
GH Research PLC (GHRS) Stock Rating & Analysis
As of October 6, 2026, MELANY rates GH Research PLC 66 out of 100 (Favorable). Its highest factor score is analyst sentiment at 87, and its lowest is business quality at 28.
MELANY ratingRated 2026-10-06GHRS · composite score
About GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company developing a treatment for depression, initially focused on proprietary mebufotenin therapies for patients with Treatment-Resistant Depression (TRD). Its portfolio includes GH001, an inhalable mebufotenin candidate, and GH002, an intravenous mebufotenin candidate, and it operates in a single Research and Development segment.
Rating as of 2026-10-06 · this is a dated snapshot; the live rating is in the app (Pro, free for 30 days). The price above updates in real time.
Why GHRS scores 66/100
GHRS's 8 factor scores run from 28 to 87, and 3 of them sit above its composite of 66. Here is how GHRS breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
Margins, returns on capital, and balance-sheet strength.
Direction and relative strength of the recent share-price trend.
- 50-day MA above 200-day (golden cross zone)
History of beating or missing estimates, and where estimates are heading.
- Beat EPS estimates 3 of last 4 quarters
- Avg EPS beat +9%
- Earnings in 30 days (strong beat history)
What Wall Street price targets and revisions are signalling.
- Analyst targets 101% upside
- Institutional net buying +6.4%
Near-term events that could move the stock.
- Earnings in 30 days
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
Key risks for GHRS
- Negative free cash flow, company consuming cash, not generating it
- No positive trailing earnings, valuation cannot be anchored to current P/E
Sector and theme context
GH Research PLC sits in the Healthcare sector theme, which MELANY currently rates 37/100 for strength. Theme strength feeds GHRS's momentum and catalyst factors above.
GHRS trade plan (Pro)
MELANY has a full position plan for GH Research PLC: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It is part of Market Eyes Pro, and the first 30 days are free.
How MELANY rates GHRS
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. GH Research PLC's 66/100 reflects speculative factor weighting for its profile. Position framework managed by score-based check-ins, not a fixed holding period.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about GHRS
Is GH Research PLC (GHRS) a buy?
As of 2026-10-06, MELANY rated GH Research PLC Favorable with a composite score of 66/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is GH Research PLC's MELANY score?
GH Research PLC (GHRS) has a MELANY composite score of 66/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, macro fit.
How is the GHRS stock rating calculated?
MELANY scores GHRS from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy GH Research PLC stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates GH Research PLC (GHRS) Favorable with a composite of 66/100 as of 2026-10-06. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the GHRS stock price forecast?
MELANY does not publish price targets or forecasts for GHRS. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 66/100 across eight factors for GH Research PLC, and re-scores automatically as new price, earnings, and fundamental data arrive.
Is GHRS stock overvalued or undervalued?
MELANY's valuation factor currently reads 59/100 for GH Research PLC, where a higher score means the price looks more attractive on that measure. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives GHRS's read.
What price should I buy GHRS at?
Rather than chasing the current price, MELANY computes a smart entry zone for GHRS: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels are part of Market Eyes Pro, which starts with a 30-day free trial.
What are the risks of buying GHRS stock?
The top risks MELANY currently flags for GH Research PLC: Negative free cash flow, company consuming cash, not generating it; No positive trailing earnings, valuation cannot be anchored to current P/E. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is GH Research PLC a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 28/100 for GH Research PLC, and earnings track record, at 80/100. The 66/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will GHRS stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 52/100 for GHRS right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this GHRS rating?
The rating on this page is a snapshot of MELANY's read as of 2026-10-06. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores GHRS continuously as new price, earnings, and fundamental data arrive, and the current rating is in the app (Pro, free for 30 days).
How this rating works
Market Eyes Live
Every rating graded in public, GHRS included
MELANY scores more than 11,000 U.S. stocks and ETFs, PRISM ranks conviction and APEX writes the plan with one entry zone. Free to start on iOS and the web.